Remarks

In response to the Notice, Applicants submit herewith a paper copy of a replacement Sequence Listing for insertion into the specification. In addition, a "Statement in Compliance with 37 C.F.R. § 1.821(f)" and a computer readable form of sequence listing are submitted herewith.

Claims 1, 4, 5, 6, 8, 9, and 14 are amended to refer to formal sequence identifiers, and the specification has been amended to replace the Sequence Listing (26 pages). The replacement Sequence Listing now includes SEQ ID NO: 43 and SEQ ID NO: 44, which correspond to the two consensus sequences that are the "middle" segments of the claimed interferon alpha hybrids. For easy reference, SEQ ID NO: 43 (LDKFXTELXQQLND) is the sequence of interferon- α 2c except for variable positions 86 and 90, and SEQ ID NO: 44 (LEKFXTELXQQLND), is the sequence of interferon- α 21a except for variable positions 86 and 90. These sequences are supported throughout the original specification, *e.g.*, at page 4, lines 12-23; page 5, lines 31-35; page 11, line 9 through page 13, line 2, page 16, lines 19-20; and page 17, lines 29-31. Specifically regarding variability at residues 86 or 90, the Examiner's attention is directed to page 6, lines 18-19, which states that position 86 or 90 can be further mutated to "other amino acids." No new matter is added by this amendment.

Conclusion

No new matter is introduced by this Amendment. Applicants believe the subject application is in condition for examination, which action is requested. If any minor matters remain prior to examination, please contact the undersigned at the telephone number listed below.

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D. Registration No. 42,630